Sigilon Therapeutics Inc logo

Sigilon Therapeutics Inc Share Price (NASDAQ: SGTX)

▲

-22.47

(-100%)

Last updated on

Bell Icon

This instrument is not available for trading on the INDmoney app on 10 Aug 2023

Check the interactive Sigilon Therapeutics Inc Stock chart to analyse performance

Sigilon Therapeutics Inc Key Stats

Check Sigilon Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$22.47
Open
$22.9
Market Capitalization
$57.5M
Today's Volume
$83.7K
Revenue TTM
$14.6M
EBITDA
$-36.2M
Earnings Per Share (EPS)
$-14.83
Dividend Yield
0.0%
Profit Margin
-253.33%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-75.77%

Global Institutional Holdings in Sigilon Therapeutics Inc

  • Name

    Holdings %

  • Flagship Ventures Management, Inc.

    31.88%

  • Canada Pension Plan Investment Board

    4.57%

  • FMR Inc

    3.24%

  • BlackRock Inc

    3.23%

  • Cercano Management LLC

    2.72%

  • Harbourvest Partners, LLC

    2.28%

Analyst Recommendation on Sigilon Therapeutics Inc Stock

Rating
Trend

Buy

    66%Buy

    33%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Sigilon Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Sigilon Therapeutics Inc

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Organization
Sigilon Therapeutics Inc
Employees
62
CEO
Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA
Industry
Miscellaneous

Important FAQs about investing in SGTX Stock from India :

What is Sigilon Therapeutics Inc share price today?

Sigilon Therapeutics Inc share price today is as on at the close of the market. Sigilon Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Sigilon Therapeutics Inc share?

Sigilon Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Sigilon Therapeutics Inc stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Sigilon Therapeutics Inc Stock (SGTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Sigilon Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sigilon Therapeutics Inc Shares .

What is the minimum amount required to buy Sigilon Therapeutics Inc Stock (SGTX) from India?

Indian investors can start investing in Sigilon Therapeutics Inc (SGTX) shares with as little as ₹93.0575 or $1 (as of April 07, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹930.58 in Sigilon Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on April 07, 2026). Learn more about fractional shares .

What are the returns that Sigilon Therapeutics Inc has given to Indian investors in the last 5 years?

Sigilon Therapeutics Inc stock has given 0.0% share price returns and 26.63% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?